Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO John F. Crowley sold 71,735 shares of the company’s stock in a transaction that occurred on Wednesday, October 18th. The shares were sold at an average price of $14.75, for a total value of $1,058,091.25. Following the transaction, the chief executive officer now owns 380,723 shares of the company’s stock, valued at approximately $5,615,664.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Amicus Therapeutics, Inc. (FOLD) traded up 0.49% on Thursday, hitting $14.31. The stock had a trading volume of 2,702,713 shares. The company has a 50 day moving average price of $14.45 and a 200-day moving average price of $11.05. The company’s market cap is $2.35 billion. Amicus Therapeutics, Inc. has a 52-week low of $4.41 and a 52-week high of $16.60.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.03. The company had revenue of $7.16 million during the quarter, compared to analysts’ expectations of $6.96 million. Amicus Therapeutics had a negative return on equity of 61.25% and a negative net margin of 1,279.88%. During the same quarter in the prior year, the firm posted ($0.40) EPS. On average, equities research analysts predict that Amicus Therapeutics, Inc. will post ($1.32) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “John F. Crowley Sells 71,735 Shares of Amicus Therapeutics, Inc. (FOLD) Stock” was posted by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/10/19/john-f-crowley-sells-71735-shares-of-amicus-therapeutics-inc-fold-stock.html.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in FOLD. Russell Investments Group Ltd. raised its holdings in Amicus Therapeutics by 1,004.9% in the 1st quarter. Russell Investments Group Ltd. now owns 121,338 shares of the biopharmaceutical company’s stock worth $865,000 after purchasing an additional 110,356 shares during the period. Wells Fargo & Company MN raised its holdings in Amicus Therapeutics by 51.7% in the 1st quarter. Wells Fargo & Company MN now owns 153,473 shares of the biopharmaceutical company’s stock worth $1,094,000 after purchasing an additional 52,287 shares during the period. Bank of New York Mellon Corp raised its holdings in Amicus Therapeutics by 12.5% in the 1st quarter. Bank of New York Mellon Corp now owns 672,463 shares of the biopharmaceutical company’s stock worth $4,794,000 after purchasing an additional 74,700 shares during the period. UBS Asset Management Americas Inc. raised its holdings in Amicus Therapeutics by 71.8% in the 1st quarter. UBS Asset Management Americas Inc. now owns 50,674 shares of the biopharmaceutical company’s stock worth $361,000 after purchasing an additional 21,174 shares during the period. Finally, JPMorgan Chase & Co. raised its holdings in Amicus Therapeutics by 3.2% in the 1st quarter. JPMorgan Chase & Co. now owns 1,465,914 shares of the biopharmaceutical company’s stock worth $10,452,000 after purchasing an additional 44,828 shares during the period.

FOLD has been the subject of a number of recent analyst reports. BidaskClub upgraded Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 24th. Robert W. Baird reaffirmed an “outperform” rating and issued a $12.00 price target on shares of Amicus Therapeutics in a research note on Friday, June 30th. Cowen and Company reaffirmed a “buy” rating and issued a $16.00 price target (up from $10.00) on shares of Amicus Therapeutics in a research note on Tuesday, July 11th. Zacks Investment Research cut Amicus Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, July 12th. Finally, J P Morgan Chase & Co reissued an “overweight” rating and issued a $15.00 target price (up from $13.00) on shares of Amicus Therapeutics in a research note on Wednesday, August 9th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Amicus Therapeutics has an average rating of “Buy” and a consensus price target of $17.81.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Insider Buying and Selling by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.